Hikal Limited — Investor Meet, 27-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Hikal's Q4 FY26 revenue was Rs. 519 Cr, with an EBITDA margin of 20.3% and PAT of Rs. 14 Cr. For FY26, revenue was Rs. 1,713 Cr, EBITDA margin 12.9%, and Net Profit (excluding exceptional items) stood at Rs. 5 Cr. The company's Q4 performance demonstrated significant operational improvement, indicating a move towards sustainable growth. The Pharmaceutical business saw improved demand and a robust CDMO pipeline, with new strategic investments now fully operational. Crop Protection demand is recovering, leading to increased order inflows. Diversification into Specialty Chemicals and Personal Care segments is on track for commercialization in FY27, setting a strong foundation for future growth.